GenScript Receives “Best Contract Development and Manufacturing Organization Award” For the Third Time in a Row


GenScript Biotech Corporation receives the “Best Contract Development and Manufacturing Organization Award” on the Asia Pacific Bioprocessing Excellence Awards 2022. This marks the third consecutive year of GenScript bagging the same award in Asia Pacific region. The award also follows GenScript’s recognition at the Korea Bioprocessing Excellence Awards in 2021 for the “Best Contract Development and Manufacturing Organization Award”.

“We are honored to be recognized once again by our customers and industry peers as the leading CDMO service partner to the biopharmaceutical industry. This award is a solid testament to our continuous effort and dedication to maintain our global position as the top solutions and service provider to accelerate drug development, next generation vaccines and therapies”, said Dr. Kun Yin, Senior Director of Business Development, GenScript ProBio Asia Pacific division. “We will continue to strive for excellence by leveraging our technology platforms and expertise to provide the best solution to our customers and partners.”

Asia Pacific Bioprocessing Excellence Awards 2022 recognizes exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost, and superior quality. The panel of expert judges include Key Opinion Leaders with more than 20 years of experience, Process Development Vice Presidents and Directors, Heads of Manufacturing and Bioprocessing from all the key players in Asia and globally. GenScript emerges as the winner for the best CDMO award among the industry peers in Asia Pacific region.

In January 2022, GenScript ProBio, which is the CDMO division of GenScript broke ground for the construction of its newest 34,000 square meter plasmid and viral vector manufacturing facility. The facility will be state-of-the-art, utilizing the latest technology and equipment in viral vector and plasmid manufacturing to scale up its production capacity and deliver end-to-end cell and gene therapy CDMO services. Many projects for COVID-19 mRNA vaccine from China have been carried out in GenScript ProBio’s plasmid manufacturing facility. Besides supporting many mRNA vaccine enterprises in China to obtain clinical approvals by NMPA, GenScript ProBio also helped mRNA vaccine projects from South Korea and the United States companies to obtain clinical approvals in South Korea and Japan.

“Cell and gene therapy is the forefront of innovation to treat severe and rare diseases, in the coming years, GenScript will focus on putting our dedication and investment to partner with scientists and develop drugs and therapies to improve human lives.” said Dr. Kun Yin during the award ceremony.

Leave a Reply

Your email address will not be published. Required fields are marked *